Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease

Catherine M. Bollard, Barbara Savoldo, Cliona M. Rooney, Helen Heslop

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


Increased understanding of the mechanisms by which T lymphocytes recognize virus and tumor-specific antigens has fueled the use of adoptive immunotherapy for viral and malignant diseases. An ideal candidate for such treatment is Epstein-Barr virus (EBV). EBV-associated post-transplant lymphoproliferative disorder (PTLD) is a serious complication post-solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). The disease is essentially the result of suppression of cytotoxic T-cell function and despite various treatment strategies the course may still be fulminant and lethal. Therefore, an adoptive immunotherapeutic approach using ex vivo derived EBV-specific CTL offers a promising solution not only for the treatment but also as prophylaxis for PTLD. The infusion of EBV-CTL has been demonstrated to be safe and effective in allogeneic HSCT recipients and their use post-SOT is being evaluated.

Original languageEnglish (US)
Pages (from-to)139-148
Number of pages10
JournalActa Haematologica
Issue number2-3
StatePublished - Nov 10 2003


  • Adoptive immunotherapy
  • Epstein-Barr virus
  • Post-transplant lymphoproliferative disease
  • Transplantation

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease'. Together they form a unique fingerprint.

Cite this